secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001384101-24-000160
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M
---------------------------------------------------------

- Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).
- Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).
- GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.
- Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/0001384101-24-000160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/vcyt-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001384101-24-000160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer